Can Bayliss and Starling gut hormones cure a worldwide pandemic?

Journal of Physiology

Volumn 592, Issue 23, 2014, Pages 5153-5167

  Scott, R V ^a   Tan, T M ^a   Bloom, S R ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALBIGLUTIDE; AMYLIN; CHOLECYSTOKININ; CYANOCOBALAMIN; EXENDIN 4; GASTROINTESTINAL HORMONE; GHRELIN; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; LIRAGLUTIDE; LORCASERIN; OBINEPITIDE; OXYNTOMODULIN; PANCREAS POLYPEPTIDE; PEPTIDE YY; PEPTIDE YY [3-36]; PHENTERMINE PLUS TOPIRAMATE; PLACEBO; PRAMLINTIDE; RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

ACUTE PANCREATITIS; AMINO ACID SUBSTITUTION; ARTICLE; BARIATRIC SURGERY; BROWN ADIPOSE TISSUE; CALORIC INTAKE; CARDIOVASCULAR DISEASE; CONJUGATION; DIABETES MELLITUS; DIET; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MEGADOSE; DRUG WITHDRAWAL; ENERGY BALANCE; ENERGY EXPENDITURE; EXERCISE; FOOD INTAKE; GASTROINTESTINAL SYMPTOM; GASTROPLASTY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; JEJUNOILEAL BYPASS; LIFESTYLE MODIFICATION; MALABSORPTION; MENTAL DISEASE; NAUSEA; NAUSEA AND VOMITING; NONHUMAN; OBESITY; OSMOTIC MINIPUMP; PANCREAS CANCER; PLASMA HALF LIFE; PRIORITY JOURNAL; ROUX Y ANASTOMOSIS; SATIETY; SINGLE DRUG DOSE; SLEEVE GASTRECTOMY; STOMACH BYPASS; THERMOGENESIS; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT REDUCTION; ANIMAL; APPETITE; AWARDS AND PRIZES; ENERGY METABOLISM; FEMALE; HEALTH CARE ORGANIZATION; MALE; PANDEMIC; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; APPETITE; APPETITE REGULATION; AWARDS AND PRIZES; BARIATRIC SURGERY; ENERGY METABOLISM; FEMALE; GASTROINTESTINAL HORMONES; GLUCAGON-LIKE PEPTIDE 1; HUMANS; MALE; OBESITY; PANDEMICS; PEPTIDE YY; SOCIETIES, SCIENTIFIC;

EID: 84918834476     PISSN: 00223751     EISSN: 14697793     Source Type: Journal    
DOI: 10.1113/jphysiol.2014.272955     Document Type: Article

References (162)

1. Acosta A, Hurtado MD, Gorbatyuk O, La Sala M, Duncan D, Aslanidi G, Campbell-Thompson M, Zhang L, Herzog H, Voutetakis A, Baum BJ & Zolotukhin S (2011). Salivary PYY: a putative bypass to satiety. PLoS One 6, e26137.
2. Adams SH, Lei C, Jodka CM, Nikoulina SE, Hoyt JA, Gedulin B, Mack CM & Kendall ES (2006). J Nutr 136, 195-201.
3. Adrian TE, Bloom SR, Bryant MG, Polak JM, Heitz PH & Barnes AJ (1976). Distribution and release of human pancreatic polypeptide. Gut 17, 940-944.
4. Adrian TE, Ferri GL, Bacarese-Hamilton AJ, Fuessl HS, Polak JM & Bloom SR (1985). Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 89, 1070-1077
5. Arnelo U, Herrington MK, Theodorsson E, Adrian TE, Reidelberger R, Larsson J, Marcusson J, Strömmer L, Ding X & Permert J (2000). Effects of long-term infusion of anorexic concentrations of islet amyloid polypeptide on neurotransmitters and neuropeptides in rat brain. Brain Res 887, 391-398.
6. Asakawa A, Inui A, Yuzuriha H, Ueno N, Katsuura G, Fujimiya M, Fujino MA, Niijima A, Meguid MM & Kasuga M (2003). Characterization of the effects of pancreatic polypeptide in the regulation of energy balance. Gastroenterology 124, 1325-1336.
7. Asakawa A, Uemoto M, Ueno N, Katagi M, Fujimiya M, Fujino K, Kodama N, Nanba H, Sakamaki R, Shinfuku N, Meguid MM & Inui A (2006). Peptide YY3-36 and pancreatic polypeptide suppress food intake. J Gastroenterol Hepatol 21, 1501-1502.
8. Astrup A, Carraro R, Finer N, Harper A, Kunesova M, Lean ME, Niskanen L, Rasmussen MF, Rissanen A, Rössner S, Savolainen MJ & Van Gaal L (2012). Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond) 36, 843-854.
9. Astrup A, Rössner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M, Madsen J, Rasmussen MF & Lean ME (2009). Effects of liraglutide in the treatment of obesity: a randomised double-blind, placebo-controlled study. Lancet 374, 1606-1616.
10. Baggio LL, Huang Q, Brown TJ & Drucker DJ (2004). Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology 127, 546-558.
11. Baldissera FG, Holst JJ, Knuhtsen S, Hilsted L & Nielsen OV (1988). Oxyntomodulin (glicentin-(33-69)): pharmacokinetics, binding to liver cell membranes, effects on isolated perfused pig pancreas, and secretion from isolated perfused lower small intestine of pigs. Regul Pept 21, 151-166.
12. Banwell JG, Northam BE & Cooke WT (1967). Secretory response of the human pancreas to continuous intravenous infusion of pancreozymin-cholecystokinin (Cecekin). Gut 8, 380-387.
13. Barnett BP, Hwang Y, Taylor MS, Kirchner H, Pfluger PT, Bernard V, Lin YY, Bowers EM, Mukherjee C, Song WJ, Longo PA, Leahy DJ, Hussain MA, Tschöp MH, Boeke JD & Cole PA (2010). Glucose and weight control in mice with a designed ghrelin O-acyltransferase inhibitor. Science 330, 1689-1692.
14. Bataille D, Gespach C, Coudray AM & Rosselin G (1981a). 'Enteroglucagon': a specific effect on gastric glands isolated from the rat fundus. Evidence for an 'oxyntomodulin' action. Biosci Rep 1, 151-155.
15. Bataille D, Gespach C, Tatemoto K, Marie JC, Coudray AM, Rosselin G & Mutt V (1981b). Bioactive enteroglucagon (oxyntomodulin): present knowledge on its chemical structure and its biological activities. Peptides 2(Suppl. 2), 41-44.
16. Batterham RL, Cohen MA, Ellis SM, Le Roux CW, Withers DJ, Frost GS, Ghatei MA & Bloom SR (2003). Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 349, 941-948.
17. Batterham RL, Cowley MA, Small CJ, Herzog H, Cohen MA, Dakin CL, Wren AM, Brynes AE, Low MJ, Ghatei MA, Cone RD & Bloom SR (2002). Gut hormone PYY3-36 physiologically inhibits food intake. Nature 418, 650-654.
18. Batterham RL, Le Roux CW, Cohen MA, Park AJ, Ellis SM, Patterson M, Frost GS, Ghatei MA & Bloom SR (2003b). Pancreatic polypeptide reduces appetite and food intake in humans. J Clin Endocrinol Metab 88, 3989-3992.
19. Beckman LM, Beckman TR & Earthman CP (2010). Changes in gastrointestinal hormones and leptin after Roux-en-Y gastric bypass procedure: a review. J Am Diet Assoc 110, 571-584.
20. Beglinger C, Poller B, Arbit E, Ganzoni C, Gass S, Gomez-Orellana I & Drewe J (2008). Pharmacokinetics and pharmacodynamics effects of oral GLP-1 and PYY3-36: a proof-of-concept study in healthy subjects. Clin Pharmacol Ther 84, 468-474.
21. Bell GI, Santerre RF & Mullenbach GT (1983). Hamster preproglucagon contains the sequence of glucagon and two related peptides. Nature 302, 716-718.
22. Berthoud HR (2012). The neurobiology of food intake in an obesogenic environment. Proc Nutr Soc 71, 478-487.
23. Blomqvist AG & Herzog H (1997). Y-receptor subtypes - how many more? Trends Neurosci 20, 294-298.
24. Blume CA, Boni CC, Casagrande DS, Rizzolli J, Padoin AV & Mottin CC (2012). Nutritional profile of patients before and after Roux-en-Y gastric bypass: 3-year follow-up. Obes Surg 22, 1676-1685.
25. Bradley EL 3rd, Isaacs JT, Mazo JD, Hersh T & Chey WY (1977). Pathophysiology and significance of malabsorption after Roux-en-Y reconstruction. Surgery 81, 684-691.
26. Buchwald H, Estok R, Fahrbach K, Banel D & Sledge I (2007). Trends in mortality in bariatric surgery: a systematic review and meta-analysis. Surgery 142, 621-632.
27. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M & Blonde L; LEAD-6 Study Group (2009). Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374, 39-47.
28. Chance WT, Balasubramaniam A, Stallion A & Fischer JE (1993). Anorexia following the systemic injection of amylin. Brain Res 607, 185-188.
29. Chance WT, Balasubramaniam A, Zhang FS, Wimalawansa SJ & Fischer JE (1991). Anorexia following the intrahypothalamic administration of amylin. Brain Res 539, 352-354.
30. Chandarana K, Gelegen C, Irvine EE, Choudhury AI, Amouyal C, Andreelli F, Withers DJ & Batterham RL (2013). Peripheral activation of the Y2-receptor promotes secretion of GLP-1 and improves glucose tolerance. Mol Metab 2, 142-152.
31. Christensen R, Kristensen PK, Bartels EM, Bliddal H & Astrup A (2007). Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 370, 1706-1713.
32. Clardy-James S, Chepurny OG, Leech CA, Holz GG & Doyle RP (2013). Synthesis, characterization and pharmacodynamics of vitamin-B(12)-conjugated glucagon-like peptide-1. Chem MedChem 8, 582-586.
33. Clark JR, Kalra PS, Crowley WR & Kalra SP (1984). Neuropeptide Y and human pancreatic polypeptide stimulate feeding behaviour in rats. Endocrinology 115, 427-429.
34. Cohen MA, Ellis SM, Le Roux CW, Batterham RL, Park A, Patterson M, Frost GS, Ghatei MA & Bloom SR (2003). Oxyntomodulin suppresses appetite and reduces food intake in humans. J Clin Endocrinol Metab 88, 4696-4701.
35. Colquitt JL, Picot J, Loveman E & Clegg AJ (2009). Surgery for obesity. Cochrane Database Syst Rev, CD003641.
36. Costantini VJ, Vicentini E, Sabbatini FM, Valerio E, Lepore S, Tessari M, Sartori M, Michielin F, Melotto S, Bifone A, Pich EM & Corsi M (2011). GSK1614343, a novel ghrelin receptor antagonist, produces an unexpected increase of food intake and body weight in rodents and dogs. Neuroendocrinology 94, 158-168.
37. Crawley JN & Beinfeld MC (1983). Rapid development of tolerance to the behavioural actions of cholecystokinin. Nature 302, 703-706.
38. Cummings DE & Cohen RV (2014). Beyond BMI:, the need for new guidelines governing the use of bariatric and metabolic surgery. Lancet Diabetes Endocrinol 2, 175-181.
39. Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE & Weigle DS (2001). A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 50, 1714-1719.
40. Dakin CL, Gunn I, Small CJ, Edwards CM, Hay DL, Smith DM, Ghatei MA & Bloom SR (2001). Oxyntomodulin inhibits food intake in the rat. Endocrinology 142, 4244-4250.
41. Dakin CL, Small CJ, Batterham RL, Neary NM, Cohen MA, Patterson M, Ghatei MA & Bloom SR (2004). Peripheral oxyntomodulin reduces food intake and body weight gain in rats. Endocrinology 145, 2687-2695.
42. Dakin CL, Small CJ, Park AJ, Seth A, Ghatei MA & Bloom SR (2002). Repeated ICV administration of oxyntomodulin causes a greater reduction in body weight gain than in pair-fed rats. Am J Physiol Endocrinol Metab 283, E1177-E1177.
43. Date Y, Kojima M, Hosoda H, Sawaguchi A, Mondal MS, Suganuma T, Matsukura S, Kangawa K & Nakazato M (2000). Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology 141, 4255-4261.
44. Day JW, Gelfanov V, Smiley D, Carrington PE, Eiermann G, Chicchi G, Erion MD, Gidda J, Thornberry NA, Tschöp MH, Marsh DJ, Sinha Roy R, DiMarchi R & Pocai A (2012). Optimization of co-agonism at GLP-1 and glucagon receptors to safely maximize weight reduction in DIO-rodents. Biopolymers 98, 443-450.
45. Day JW, Ottaway N, Patterson JT, Gelfanov V, Smiley D, Gidda J, Findeisen H, Bruemmer D, Drucker DJ, Chaudhary N, Holland J, Hembree J, Abplanalp W, Grant E, Ruehl J, Wilson H, Kirchner H, Lockie SH, Hofmann S, Woods SC, Nogueiras R, Pfluger PT, Perez-Tilve D, Di-Marchi R & Tschöp MH (2009). A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol 5, 749-757.
46. De Burgh Daly I (1967). The Second Bayliss-Starling Memorial Lecture. Some aspects of their separate and combined research interests. J Physiol 191, 1-23.
47. Dennis MS, Zhang M, Meng YG, Kadkhodayan M, Kirchhofer D, Combs D & Damico LA (2002). Albumin binding as a general strategy for improving the pharmacokinetics of proteins. J Biol Chem 277, 35035-35043.
48. Depigny C, Lupo B, Kervran A & Bataille D (1984). [Demonstration of a specific receptor site for glucagon-37 (oxyntomodulin/bioactive enteroglucagon) in rat oxyntic glands]. C R Acad Sci III 299, 677-680 (In French.)
49. De Silva A & Bloom SR (2012). Gut hormones and appetite control:, a focus on PYY and GLP-1 as therapeutic targes in obesity. Gut Liver 6, 10-20.
50. Dirksen C, Bojsen-Møller KN, Jørgensen NB, Jacobsen SH, Kristiansen VB, Naver LS, Hansen DL, Worm D, Holst JJ & Madsbad S (2013). Exaggerated release and preserved insulinotropic action of glucagon-like peptide-1 underlie insulin hypersecretion in glucose-tolerant individuals after Roux-en-Y gastric bypass. Diabetologia 56, 2679-2687.
51. Dockray GJ ( 2014), Gastrointestinal hormones and the dialogue between gut and brain. J Physiol 592, 2927-2941.
52. Druce MR, Wren AM, Park AJ, Milton JE, Patterson M, Frost G, Ghatei MA, Small C & Bloom SR (2005). Ghrelin increases food intake in obese as well as lean subjects. Int J Obes (Lond) 29, 1130-1136.
53. Egan AG, Blind E, Dunder K, de Graeff PA, Hummer BT, Bourcier T & Rosebraugh C (2014). Pancreatic safety of incretin-based drugs-FDA and EMA assessment. N Engl J Med 370, 794-797.
54. Eng J, Kleinman WA, Singh L, Singh G & Raufman JP (1992). Isolation and characterization of exendin-4, and exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 267, 7402-7405.
55. Esler WP, Rudolph J, Claus TH, Tang W, Barucci N, Brown SE, Bullock W, Daly M, Decarr L, Li Y, Milardo L, Molstad D, Zhu J, Gardell SJ, Livingston JN & Sweet LJ (2007). Endocrinology 148, 5175-5185.
56. Falkén Y, Hellström PM, Holst JJ & Näslund E (2011). Changes in glucose homeostasis after Roux-en-Y gastric bypass surgery for obesity at day three, two months, and one year after surgery: role of gut peptides. J Clin Endocrinol Metab 96, 2227-2235.
57. Farooqi IS, Bullmore E, Keogh J, Gillard J, O'Rahilly S & Fletcher PC (2007). Leptin regulates striatal regions and human eating behavior. Science 317, 1355.
58. Fazen CH, Valentin D, Fairchild TJ & Doyle RP (2011). Oral delivery of the appetite suppressing peptide hPYY(3-36) through the vitamin B12 uptake pathway. J Med Chem 54, 8707-8711
59. Field BC, Wren AM, Peters V, Baynes KC, Martin NM, Patterson M, Alsaraf S, Amber V, Wynne K, Ghatei MA & Bloom SR (2010). PYY3-36 and oxyntomodulin can be additive in their effect on food intake in overweight and obese humans. Diabetes 59, 1635-1639.
60. Flint A, Raben A, Astrup A & Holst JJ (1998). Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 101, 515-520.
61. Flynn MC, Scott TR, Pritchard TC & Plata-Salamán CR (1998) Mode of action of OB protein (leptin) on feeding. Am J Physiol Regul Integr Comp Physiol 275, R174-R179.
62. Franz MJ, Van Wormer JJ, Crain AL, Boucher JL, Histon T, Caplan W, Bowman JD & Pronk NP (2007). Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow up. J Am Diet Assoc 107, 1755-1767.
63. Gantz I, Erondu N, Mallick M, Musser B, Krishna R, Tanaka WK, Snyder K, Stevens C, Stroh MA, Zhu H, Wagner JA, Macneil DJ, Heymsfield SB & Amatruda JM (2007). Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults. J Clin Endocrinol Metab 92, 1754-1757.
64. Gault VA, Bhat VK, Irwin N & Flatt PR (2013). A novel glucagon-like peptide-1 (GLP-1)/glucagon hybrid peptide with triple-acting agonist activity at glucose-dependent insulinotropic polypeptide GLP-1, and glucagon receptors and therapeutic potential in high fat-fed mice. J Biol Chem 288, 35581-35591.
65. Gerner T, Johansen OE, Olufsen M, Torjesen PA & Tveit A (2014). The post-prandial pattern of gut hormones is related to magnitude of weight-loss following gastric bypass surgery: a case-control study. Scand J Clin Lab Invest 74, 213-218.
66. Gibbs J, Young RC & Smith GP (1997). Cholecystokinin decreases food intake in rats. 1973. Obes Res 5, 284-290.
67. Gibbs J, Young RC & Smith GP (1973a). Cholecystokinin decreases food intake in rats. J Comp Physiol Psychol 84, 488-495.
68. Gibbs J, Young RC & Smith GP (1973b). Cholecystokinin elicits satiety in rats with open gastric fistulas. Nature 245, 323-325.
69. Global Health Observatory (2008). Overweight and obesity. http://www.who.int/gho/ncd/risk_factors/overweight/en/
70. Griffen WO Jr, Young VL & Stevenson CC (1977). A prospective comparison of gastric and jejunoileal bypass procedures for morbid obesity. Ann Surg 186, 500-509.
71. Gros L, Thorens B, Bataille D & Kervran A (1993). Glucagon-like peptide-1-(7-36) amide, oxyntomodulin, and glucagon interact with a common receptor in a somatostatin-secreting cell line. Endocrinology 133, 631-638.
72. Guo L, Sans MD, Hou Y, Ernst SA & Williams JA (2012). c-Jun/AP-1 is required for CCK-induced pancreatic acinar cell dedifferentiation and DNA synthesis in vitro. Am J Physiol Gastrointest Liver Physiol 302, G1381-G1396.
73. Halem HA, Taylor JE, Dong JZ, Shen Y, Datta R, Abizaid A, Diano S, Horvath TL & Culler MD (2005). A novel growth hormone secretagogue-1a receptor antagonist that blocks ghrelin-induced growth hormone secretion but induces increased body weight gain. Neuroendocrinology 81, 339-349.
74. Henry RR, Rosenstock J, Logan D, Alessi T, Luskey K & Baron MA (2014). Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes. J Diabetes Complications 28, 393-398.
75. Hershkovitz O, Bar-Ilan A, Hart G & Fima E (2013). The long-acting dual GLP-1/glucagon agonist MOD-6030 improves glycemic control and induces a prolonged weight loss in diet induced obesity mice following a once weekly administration. ENDO 2013 Abstracts, FP02-3.
76. Hisadome K, Reimann F, Gribble FM & Trapp S (2011). CCK stimulation of GLP-1 neurons involves α1-adrenoceptor-mediated increase in glutamatergic synaptic inputs. Diabetes 60, 2701-2709.
77. Homaee HM, Moradi F, Azarbayjani MA & Peeri M (2011). Relationships between acylated ghrelin with growth hormone, insulin resistance, lipid profile, and cardio-respiratory function in lean and obese men. J Res Med Sci 16, 1612-1618.
78. Kenler HA, Brolin RE & Cody RP (1990). Changes in eating behaviour after horizontal gastroplasty and Roux-en-Y gastric bypass. Am J Clin Nutr 52, 87-92.
79. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H & Kangawa K (1999). Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402, 656-660.
80. Korner J, Inabnet W, Febres G, Conwell IM, McMahon DJ, Salas R, Taveras C, Schrope B & Bessler M (2009). Prospective study of gut hormone and metabolic changes after adjustable gastric banding and Roux-en-Y gastric bypass. Int J Obes (Lond) 33, 786-795
81. Ivy AC & Oldberg W (1928). A hormone mechanism for gallbladder contraction and evacuation. Am J Physiol 86, 599-613.
82. Jacobsen SH, Olesen SC, Dirksen C, Jørgensen NB, Bojsen-Møller KN, Kielgast U, Worm D, Almdal T, Naver LS, Hvolris LE, Rehfeld JF, Wulff BS, Clausen TR, Hansen DL, Holst JJ & Madsbad S (2012). Changes in gastrointestinal hormone responses, insulin sensitivity, and beta-cell function within 2 weeks after gastric bypass in non-diabetic subjects. Obes Surg 22, 1084-1096.
83. James WP, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggioni AP, Torp-Pedersen C, Sharma AM, Shepherd GM, Rode RA, Renz CL & SCOUT Investigators (2010). Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 363, 905-917.
84. Kalra SP, Dube MG, Fournier A & Kalra PS (1991). Structure-function analysis of stimulation of food intake by neuropeptide Y: effects of receptor agonists. Physiol Behav 50, 5-9.
85. Kanatani A, Mashiko S, Murai N, Sugimoto N, Ito J, Fukuroda T, Fukami T, Morin N, MacNeil DJ, Van der Ploeg LH, Saga Y, Nishimura S & Ihara M (2000). Role of the Y1 receptor in the regulation of neuropeptide Y-mediated feeding: comparison of wild-type Y1 receptor-deficient, and Y5 receptor-deficient mice. Endocrinology 141, 1011-1016.
86. 34]PYY, and PYY-(3-36) confer different conformation and receptor selectivity. Am J Physiol Gastrointest Liver Physiol 279, G126-G131.
87. Kenler JA, Brolin RE & Cody RP (1990). Changes in eating behaviour after horizontal gastroplasty and Roux-en-Y gastric bypass. Am J Clin Nutr 52, 87-92.
88. Kissileff HR, Pi-Sunyer FX, Thornton J & Smith GP (1981). C-terminal octapeptide of cholecystokinin decreases food intake in man. Am J Clin Nutr 34, 154-160.
89. Korner J, Inabnet W, Conwell IM, Taveras C, Daud A, Olivero-Rivera L, Restuccia NL & Bessler M (2006). Differential effects of gastric bypass and banding on circulating gut hormone and leptin levels. Obesity (Silver Spring) 14, 1553-1561.
90. Korner J, Inabnet W, Febres G, Conwell IM, McMahon DJ, Salas R, Taveras C, Schrope B & Bessler M (2009). Prospective study of gut hormone and metabolic changes after adjustable gastric banding and Roux-en-Y gastric bypass. Int J Obes (Lond) 33, 786-795.
91. Kosinski JR, Hubert J, Carrington PE, Chicchi GG, Mu J, Miller C, Cao J, Bianchi E, Pessi A, Sinharoy R, Marsh DJ & Pocai A (2012). The glucagon receptor is involved in mediating the body weight-lowering effects of oxyntomodulin. Obesity 20, 1566-1571.
92. Laferrère B, Swerdlow N, Bawa B, Arias S, Bose M, Oliván B, Teixeira J, McGinty J & Rother KI (2010). Rise of oxyntomodulin in response to oral glucose after gastric bypass surgery in patients with type 2 diabetes. J Clin Endocrinol Metab 95, 4072-4076.
93. Li JF, Lai DD, Lin ZH, Jiang TY, Zhang AM & Dai JF (2014). Comparison of the long-term results of Roux-en-Y gastric bypass and sleeve gastrectomy for morbid obesity: a systematic review and meta-analysis of randomized and nonrandomized trials. Surg Laparosc Endosc Percutan Tech 24, 1-11.
94. Lluis F, Fujimura M, Gómez G, Salvá JA, Greeley GH Jr & Thompson JC (1989). [Cellular localization, half-life, and secretion of peptide YY]. Rev Esp Fisiol 45, 377-384. (In Spanish.)
95. Lockie SH, Heppner KM, Chaudhary N, Chabenne JR, Morgan DA, Veyrat-Durebex C, Ananthakrishnan G, Rohner-Jeanrenaud F, Drucker DJ, DiMarchi R, Rahmouni K, Oldfield BJ, Tschöp MH & Perez-Tilve D (2012). Direct control of brown adipose tissue thermogenesis by central nervous system glucagon-like peptide-1 receptor signalling. Diabetes 61, 2753-2762.
96. Lund PK, Goodman RH, Dee PC & Habener JF (1982). Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem. Proc Natl Acad Sci U S A 79, 345-349.
97. Maclagan NF (1937). The role of appetite in the control of body weight. J Physiol 90, 385-394.
98. Mason EE & Ito C (1969). Gastric bypass. Ann Surg 170, 329-339.
99. Matthews JE, Stewart MW, De Boever EH, Dobbins RL, Hodge RJ, Walker SE, Holland MC & Bush MA; Albiglutide Study Group. (2008). Pharmacodynamics, pharmacokinetics, safety and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes. J Clin Endocrinol Metab 93, 4810-4817.
100. McPherson K, Marsh T & Brown M (2007). Modelling future trends in obesity and the impact on health. In Foresight Tackling Obesities: Future Choices - Project Report. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/295149/07-1662-obesity-modelling-trends.pdf
101. Meier JJ, Nauck MA, Kranz D, Holst JJ, Deacon CF, Gaeckler D, Schmidt WE & Gallwitz B (2004). Secretion, degradation and elimination of glucagon-like peptide 1 and gastric inhibitor polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes 53, 654-662.
102. Mentlein R, Dahms P, Grandt D & Krüger R (1993). Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV. Regul Pept 49, 133-144.
103. Meyer-Gerspach AC, Wölnerhanssen B, Beglinger B, Nessenius F, Napitupulu M, Schulte FH, Steinert RE & Beglinger C (2014). Gastric and intestinal satiation in obese and normal weight healthy people. Physiol Behav 129, 265-271.
104. Michalakis K & le Roux C (2012). Gut hormones and leptin: impact on energy control and changes after bariatric surgery - what the future holds. Obes Surg 22, 1648-1657.
105. Morley JE, Levine AS, Grace M & Kneip J (1985). Peptide YY (PYY), a potent orexigenic agent. Brain Res 341, 200-203.
106. Näslund E, Barkeling B, King N, Gutniak M, Blundell JE, Holst JJ, Rössner S & Hellström PM (1999). Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int J Obes Relat Metab Disord 23, 304-311.
107. Neary NM, McGowan BM, Monteiro MP, Jesudason DR, Ghatei MA & Bloom SR (2008). No evidence of an additive inhibitory feeding effect following PP and PYY 3-36 administration. Int J Obes (Lond) 32, 1438-1440.
108. Neary NM, Small CJ, Druce MR, Park AJ, Ellis SM, Semjonous NM, Dakin CL, Filipsson K, Wang F, Kent AS, Frost GS, Ghatei MA & Bloom SR (2005). Peptide YY3-36 and glucagon-like peptide 17-36 inhibit food additively. Endocrinology 146, 5120-5127.
109. Needham J (1936). Order and Life. Yale University Press.
110. NICE (2006). Obesity: guidance on the prevention, identification, assessment and management of overweight and obesity in adults and children. NICE Clinical Guideline 43. http://www.nice.org.uk/nicemedia/live/11000/30365/30365.pdf
111. Niederau C, Liddle RA, Ferrell LD & Grendell JH (1986). Beneficial effects of cholecystokinin-receptor blockade and inhibition of proteolytic enzyme activity in experimental acute hemorrhagic pancreatitis in mice. Evidence for cholecystokinin as a major factor in the development of acute pancreatitis. J Clin Invest 78, 1056-1063.
112. Niswender K, Pi-Sunyer X, Buse J, Jensen KH, Toft AD, Russell-Jones D & Zinman B (2013). Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes Obes Metab 15, 42-54.
113. Norris SL, Lee N, Thakurta S & Chan BK (2009). Exenatide efficacy and safety: a systematic review. Diabet Med 26, 837-846.
114. Odstrcil EA, Martinez JG, Santa Ana CA, Xue B, Schneider RE, Steffer KJ, Porter JL, Asplin J, Kuhn JA & Fordtran JS (2010). The contribution of malabsorption to the reduction in net energy absorption after long-limb Roux-en-Y gastric bypass. Am J Clin Nutr 92, 704-713.
115. Ohlsson B, Fredäng N & Axelson J (1999). The effect of bombesin, cholecystokinin, gastrin and their antagonists on proliferation of pancreatic cancer cell lines. Scand J Gastroenterol 34, 1224-1229.
116. Parkes D, Jodka C, Smith P, Nayak S, Rinehart L, Gingerich R, Chen K & Young A (2001). Pharmacokinetic actions of exendin-4 in the rat: comparison with glucagon-like peptide-1. Drug Dev Res 53, 260-267.
117. Patterson M, Bloom SR & Gardiner JV (2011). Ghrelin and appetite control in humans - potential application in the treatment of obesity. Peptides 32, 2290-2294.
118. Picot J, Jones J, Colquitt JL, Gospodarevskaya E, Loveman E, Baxter L & Clegg AJ (2009). The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation. Health Technol Assess 13, 1-190.
119. Pi-Sunyer X, Kissileff HR, Thornton J & Smith GP (1982). C-terminal octapeptide of cholecystokinin decreases food intake in obese men. Physiol Behav 29, 627-630.
120. Pocai A, Carrington PE, Adams JR, Wright M, Eiermann G, Zhu L, Du X, Petrov A, Lassman ME, Jiang G, Liu F, Miller C, Tota LM, Zhou G, Zhang X, Sountis MM, Santoprete A, Capito' E, Chicchi GG, Thornberry N, Bianchi E, Pessi A, Marsh DJ & Sinha Roy R (2009). Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes 58, 2258-2266.
121. Pories WJ, Caro JF, Flickinger EG, Meelhein HD & Swanson MS (1987). The control of diabetes (NIDDM) in the morbidly obese with the Greenville Gastric Bypass. Ann Surg 206, 316-323.
122. Pories WJ, Dohm LG & Mansfield CJ (2010). Beyond the BMI: the search for better guidelines for bariatric surgery. Obesity 18, 865-871.
123. Pories WJ, Swanson MS, MacDonald KG, Long SB, Morris PG, Brown BM, Barakat HA, deRamon RA, Israel G, Dolezal JM & Dohm L (1995). Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg 222, 339-350.
124. Ratner RE, Want L L, Fineman MS, Velte MJ, Ruggles JA, Gottlieb A, Weyer C & Kolterman OG (2002). Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes. Diabetes Technol Ther 4, 51-61.
125. Raufman JP, Singh L, Singh G & Eng J (1992). Truncated glucagon-like peptide-1 interacts with exendin receptors on dispersed acini from guinea pig pancreas. Indentification of a mammalian analogue of the reptilian peptide exendin-4. J Biol Chem 267, 21432-21437.
126. Rosenstock J, Reusch J, Bush M, Yang F, Stewart M & Albiglutide Study Group (2009). Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing. Diabetes Care 32, 1880-1886.
127. Roth JD, Hughes H, Kendall E, Baron AD & Anderson CM (2006). Antiobesity effects of the β-cell hormone amylin in diet-induced obese rats: effects on food intake, body weight, composition, energy expenditure, and gene expression. Endocrinology 147, 5855-5864.
128. Rubino F, Forgione A, Cummings DE, Vix M, Gnuli D, Mingrone G, Castagneto M & Marescaux J (2006). The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg 244, 741-749.
129. Rucker D, Padwal R, Li SK, Curioni C & Lau DC(2007) Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 335, 1194-1199.
130. Rushing PA, Hagan MM, Seeley RJ, Lutz TA & Woods SC (2000). Amylin: a novel action in the brain to reduce body weight. Endocrinology 141, 850-853.
131. Sanke T, Bell GI, Sample C, Rubenstein AH & Steiner DF (1988). An islet amyloid peptide is derived from an 89-amino acid precursor by proteolytic processing. J Biol Chem 263, 17243-17246.
132. Schick RR, Schusdziarra V, Mössner J, Neuberger J, Schröder B, Segmüller R, Maier V & Classen M (1991). Effect of CCK on food intake in man: physiological or pharmacological effect. Z Gastroenterol 29, 53-58.
133. Schjoldager BT, Baldissera FG, Mortensen PE, Holst JJ & Christiansen J (1988). Oxyntomodulin: a potential hormone from the distal gut. Pharmacokinetics and effects on gastric acid and insulin secretion in man. Eur J Clin Invest 18, 499-503.
134. Schmidt WE, Siegel EG & Creutzfeldt W (1985). Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets. Diabetologica 28, 704-707.
135. Schmidt JB, Gregersen NT, Pedersen SD, Arentoft JL, Ritz C, Schwartz TW, Holst JJ, Astrup A & Sjödin A (2014). Effects of PYY3-36 and GLP-1 on energy intake, energy expenditure and appetite in overweight men. Am J Physiol Endocrinol Metab 306, E1248-E1256.
136. Shechter Y, Tsubery H, Mironchik M, Rubinstein M & Fridkin M (2005). Reversible PEGylation of peptide YY3-36 prolongs its inhibition of food intake in mice. FEBS Lett 579, 2439-2444.
137. Shin AC, Zheng H, Pistell PJ & Berthoud HR (2011). Roux-en-Y gastric bypass surgery changes food reward in rats. Int J Obes(Lond) 35, 642-651.
138. Singh-Franco D, Perez A & Harrington C (2011). The effect of pramlintide acetate on glycemic control and weight in patients with type 2 diabetes mellitus and in obese patients without diabetes: a systematic review and meta-analysis. Diabetes Obes Metab 13, 169-180.
139. Sjöstöm L (2013). Review of the key results from the Swedish Obese Subjects (SOS) trial - a prospective controlled intervention study of bariatric surgery. J Intern Med 273, 219-234.
140. Soares JB, Roncon-Albuquerque R Jr & Leite-Moreira A (2008). Ghrelin and ghrelin receptor inhibitors: agents in the treatment of obesity. Expert Opin Ther Targets 12, 1177-1189.
141. Steinert RE, Poller B, Castelli MC, Drewe J & Beglinger C (2010). Oral administration of glucagon-like peptide 1 or peptide YY 3-36 affects food intake in healthy male subjects. Am J Clin Nutr 92, 810-817.
142. Tan TM, Field BC, Minnion JS, Cuenco-Shillito J, Chambers ES, Zac-Varghese S, Brindley CJ, Mt-Isa S, Fiorentino F, Ashby D, Ward I, Ghatei MA & Bloom SR (2012). Pharmacokinetics, adverse effects and tolerability of a novel analogue of human pancreatic polypeptide PP 1420. Br J Clin Pharmacol 73, 232-239.
143. The Health and Social Care Information Centre (2013). Statistics on Obesity, Physical Activity and Diet: England, 2013. http://www.hscic.gov.uk/catalogue/PUB10364/obes-phys-acti-diet-eng-2013-rep.pdf
144. Thum A, Hupe-Sodmann K, Göke R, Voigt K, Göke B & McGregor GP (2002). Endoproteolysis by isolated membrane peptidases reveal metabolic stability of glucagon-like peptide-1 analogs, exendins-3 and -4. Exp Clin Endocrinol Diabetes 110, 113-118.
145. Tibble C, Cavaiola T & Henry R (2013). Longer acting GLP-1 receptor agonists and the potential for improved cardiovascular outcomes. Expert Rev Endocrinol Metab 8, 247-259.
146. Tice JA, Karliner L, Walsh J, Petersen AJ & Feldman MD (2008). Gastric banding or bypass? A systematic review comparing the two most popular bariatric procedures. Am J Med 121, 885-893.
147. Tschöp M, Smiley DL & Heiman ML (2000). Ghrelin induces adiposity in rodents. Nature 407, 908-913.
148. Tschöp M, Wawarta R, Riepl RL, Friedrich S, Bidlingmaier M, Landgraf R & Folwaczyny C (2001). Post-prandial decrease of circulating human ghrelin levels. J Endocrinol Invest 24, 19-21.
149. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CM, Meeran K, Choi SJ, Taylor GM, Heath MM, Lambert PD, Wilding JP, Smith DM, Ghatei MA, Herbert J & Bloom SR (1996). A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379, 69-72.
150. Ueno N, Inui A, Iwamoto M, Kaga T, Asakawa A, Okita M, Fujimiya M, Nakajima Y, Ohmoto Y, Ohnaka M, Nakaya Y, Miyazaki JI & Kasuga M (1999). Decreased food intake and body weight in pancreatic polypeptide-overexpressing mice. Gastroenterology 117, 1427-1432.
151. Verdich C, Flint A, Gutzwiller JP, Näslund E, Beglinger C, Hellström PM, Long SJ, Morgan LM, Holst JJ & Astrup A (2001). A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab 86, 4382-4389.
152. Vilsbøll T, Agersø H, Krarup T & Holst JJ (2003). Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 88, 220-224.
153. Whitehouse F, Kruger DF, Fineman M, Shen L, Ruggles JA, Maggs DG, Weyer C & Kolterman OG (2002). A randomised study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care 25, 724-730.
154. Wren AM, Seal LJ, Cohen MA, Brynes AE, Frost GS, Murphy KG, Dhillo WS, Ghatei MA & Bloom SR (2001a). Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 86, 5992.
155. Wren AM, Small CJ, Abbott CR, Dhillo WS, Seal LJ, Cohen MA, Batterham RL, Taheri S, Stanley SA, Ghatei MA & Bloom SR (2001b). Ghrelin causes hyperphagia and obesity in rats. Diabetes 50, 2540-2547.
156. Wren AM, Small CJ, Ward HL, Murphy KG, Dakin CL, Taheri S, Kennedy AR, Roberts GH, Morgan DG, Ghatei MA & Bloom SR (2000). The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. Endocrinology 141, 4325-4328.
157. Wynne K, Park AJ, Small CJ, Meeran K, Ghatei MA, Frost GS & Bloom SR (2006). Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial. Int J Obes (Lond) 30, 1729-1736.
158. Wynne K, Park AJ, Small CJ, Patterson M, Ellis SM, Murphy KG, Wren AM, Frost GS, Meeran K, Ghatei MA & Bloom SR (2005). Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. Diabetes 54, 2390-2395.
159. Yang J, Brown MS, Liang G, Grishin NV & Goldstein JL (2008). Identification of the acyltransferase that octanoylates ghrelin, an appetite stimulating peptide hormone. Cell 132, 387-396.
160. Young AA, Vine W, Cedulin BR, Pittner R, Janes S, Gaeta LSL, Percy A, Moore CX, Koda JE, Rink TJ & Beaumont K (1996). Preclinical pharmacology of pramlintide in the rat: comparisons with human and rat amylin. Drug Dev Res 37, 231-248.
161. Zander M, Madsbad S, Madsen JL & Holst JJ (2002). Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study. Lancet 359, 824-830.
162. Zorrilla EP, Iwasaki S, Moss JA, Chang J, Otsuji J, Inoue K, Meijler MM & Janda KD (2006). Vaccination against weight gain. Proc Natl Acad Sci U S A 103, 13226-13231.